Pharsight

Uloric patents expiration

ULORIC's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form
Mar, 2024

(5 months from now)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(7 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(7 years from now)

Uloric is owned by Takeda Pharms Usa.

Uloric contains Febuxostat.

Uloric has a total of 3 drug patents out of which 0 drug patents have expired.

Uloric was authorised for market use on 13 February, 2009.

Uloric is available in tablet;oral dosage forms.

Uloric can be used as use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline.

The generics of Uloric are possible to be released after 08 September, 2031.

Drugs and Companies using FEBUXOSTAT ingredient

Market Authorisation Date: 13 February, 2009

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

How can I launch a generic of ULORIC before it's drug patent expiration?
More Information on Dosage

ULORIC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic